FDA staff just recommended against BPC-157 and TB-500 for the compounding list

What FDA staff recommended against BPC-157 and TB-500

On June 30, 2026, FDA career scientists posted eight briefing documents ahead of the Pharmacy Compounding Advisory Committee's July 23-24 hearing. Seven cover individual peptides: BPC-157, TB-500, KPV, MOTs-C, Semax, Epitalon, and emideltide (also called DSIP). The conclusion in all seven is the same. FDA staff recommend against adding any of them to the 503A Bulk Drug Substances List, the list that would let licensed compounding pharmacies fill a prescription for these substances under formal FDA recognition.

That is a different, more specific finding than what we covered when the hearing was first scheduled. It also cuts against the read that the April 2026 reclassification, which pulled BPC-157 and TB-500 out of Category 2 restrictions, was a step toward a formal green light. Staff scientists looked at the actual nomination packages and, for BPC-157 and TB-500 specifically, found the evidence does not clear the bar.

Why BPC-157 got a no

The BPC-157 nomination FDA evaluated was not for tendon or joint healing, the use most people associate with the peptide. It was for ulcerative colitis. That matters, because it means the 44-page conclusion applies to a narrower question than most coverage suggests.

On characterization, FDA said neither BPC-157 free base nor its acetate salt is well characterized, citing naming conventions that do not follow standard chemical nomenclature and missing data on impurities, aggregates, and microbial quality. On effectiveness, FDA found a single small trial testing BPC-157 for ulcerative colitis, and called its results hard to interpret because of a thin meeting abstract and an exploratory study design. FDA did not find any studies giving BPC-157 orally, subcutaneously, nasally, or transdermally to people with the condition.

On safety, the human data consists of two small studies using BPC-157 as a rectal enema for up to two weeks. No serious adverse events turned up, but FDA said that is not enough to support long-term use in a chronic, relapsing disease like ulcerative colitis, and flagged a separate concern about immunogenicity if the peptide were formulated for injection.

TB-500's file is thinner than BPC-157's

If BPC-157 had a weak case, TB-500 had almost none. FDA said it found no clinical studies in which TB-500 was given to a person for any condition, wound healing included, which is the use in the nomination. The nominator did not submit any, either.

The closest thing to supporting evidence in the record works against the nomination. FDA identified an in-vitro study in which TB-500 free base, at a concentration of 50 micrograms per milliliter, did not promote wound healing in confluent fibroblast cultures with scratch-generated wounds. A separate TB-500 metabolite showed some wound-healing activity in the same kind of test, but FDA noted the pharmacological profile of that metabolite on its own is not established.

On historical use, FDA said it identified websites selling products containing TB-500 but could not confirm that any licensed pharmacy has actually compounded it, despite interest in the underlying compound, thymosin beta-4, going back to 2010. Combined with the same characterization gaps as BPC-157 and an identical immunogenicity concern for injectable forms, the balance came out clearly against inclusion.

The same four-factor test sank all seven

FDA weighs every 503A Bulks List nomination against four criteria: whether the substance is physically and chemically well characterized, whether it has a documented history in compounding, what evidence exists for effectiveness, and whether there are safety concerns specific to compounded use. Across all seven peptides in this round, the same gaps kept showing up. KPV, TB-500, and MOTs-C had no human clinical evidence at all. BPC-157, emideltide, and Semax had studies that were small, uncontrolled, or produced mixed results. Naming inconsistencies between free base and acetate salt forms showed up in nearly every write-up, which FDA said makes it hard to know what a given supplier is actually selling.

This is a recommendation, not a decision

Nothing here is final. The Pharmacy Compounding Advisory Committee, a panel of outside experts, votes substance by substance at the July 23-24 meeting at FDA White Oak. The committee can vote differently than staff recommended, and the public comment docket, FDA-2025-N-6895, stays open until July 22 and becomes part of what the committee sees before voting. After that, the recommendation goes to the FDA, which makes the actual determination on the Bulks List with no set timeline.

In practice, a staff conclusion this uniform, the same core problems repeating across seven unrelated peptides, is a hard recommendation for a committee to talk itself out of. It does not guarantee the outcome. It does tell you which way the weight is leaning going into the hearing.

What this means if you use BPC-157 or TB-500 today

Nothing changes this week. If the FDA ultimately follows its staff and keeps BPC-157 and TB-500 off the 503A Bulks List, the practical effect is that licensed compounding pharmacies stay barred from filling a physician-written prescription for either peptide under formal FDA authorization. The legal gray area we described after April's reclassification, where these substances are not restricted but also not affirmatively approved for compounding, would simply continue rather than resolve into a clear yes.

Research chemical vendors selling BPC-157 or TB-500 online are not licensed compounders and are not affected by any outcome from this hearing either way. For the full picture of how the April reclassification and this hearing fit together, see our breakdown of the April 2026 change and our preview of the July 23 hearing. If you are weighing BPC-157 alongside a GLP-1, our BPC-157 with a GLP-1 guide covers what the evidence actually supports today, separate from where the regulatory process lands.